Zdrowie i gospodarka · 25/09/2024
FDA Proposes Reclassification of Hepatitis B Virus Assay Devices
The FDA is proposing to reclassify certain hepatitis B virus assay devices from Class III to Class II, requiring premarket notification, and introducing new device classification regulations to ensure safety and effectiveness.
Source: Federal Register — Food and Drug AdministrationOpen original release →